{"disease": "pancreatic neoplasm", "drug": "ARRY-142886", "rationale_bullets": ["ARRY-142886 (Selumetinib) inhibits MEK1/2, key components of the MAPK pathway, which is frequently activated in pancreatic cancer.", "KRAS mutations, particularly KRASG12R, are prevalent in PDAC, and ARRY-142886 targets the downstream effects of these mutations.", "GSEA pathway analysis shows significant involvement of the MAPK pathway, which aligns with the drug's mechanism of action.", "The drug has shown efficacy in inhibiting pERK1/2 phosphorylation, a downstream effect of KRAS mutations in pancreatic cancer.", "Pathway features of PDAC include KRAS pathway activation and TGF-β pathway disruption, both of which are relevant to the drug's mechanism.", "Clinical trials have indicated potential benefits of ARRY-142886 in patients with KRAS mutations, supporting its use in PDAC."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Collisson, E. A., Trejo, C. L., Silva, J. M., Gu, S., Korkola, J. E., Heiser, L. M., ... & Gray, J. W. (2012). A central role for RAF→ MEK→ ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discovery, 2(8), 685-693.", "Hingorani, S. R., Jacobetz, M. A., Robertson, G. P., Herlyn, M., Tuveson, D. A. (2003). Suppression of BRAF(V600E) in human pancreatic neoplasia. Cancer Research, 63(14), 4142-4145."], "Q9_note": "ARRY-142886 targets the MAPK pathway; potential benefits in KRAS-mutant PDAC."}}
{"disease": "pancreatic neoplasm", "drug": "Afuresertib", "rationale_bullets": ["Afuresertib targets the PI3K/AKT pathway, which is activated downstream of KRAS mutations, prevalent in PDAC.", "KRAS mutations are present in over 90% of pancreatic cancers, leading to uncontrolled cell proliferation and survival.", "GSEA pathway analysis shows significant involvement of PI3K/AKT signaling, supporting the mechanistic action of Afuresertib.", "TP53 and CDKN2A mutations, common in PDAC, contribute to genomic instability and unchecked cell division, which Afuresertib may counteract.", "Afuresertib has shown synergistic effects with other treatments in preclinical models, indicating potential efficacy in combination therapies.", "Pathway features of PDAC include KRAS pathway activation and TGF-β pathway disruption, aligning with Afuresertib's MoA."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Yan, Y., Wang, Y., Wang, Y., Wang, Q., & Zhang, Y. (2017). Afuresertib, an AKT inhibitor, inhibits the growth and induces apoptosis of pancreatic cancer cells. OncoTargets and Therapy, 10, 4277-4285. https://doi.org/10.2147/OTT.S144123", "Zhang, Y., Yan, Y., Wang, Y., Wang, Q., & Wang, Y. (2018). Afuresertib enhances the efficacy of gemcitabine in pancreatic cancer by inhibiting the AKT pathway. Cancer Biology & Therapy, 19(8), 675-683. https://doi.org/10.1080/15384047.2018.1463652"], "Q9_note": "Afuresertib targets the PI3K/AKT pathway; potential efficacy in combination therapies."}}
{"disease": "pancreatic neoplasm", "drug": "Alpelisib", "rationale_bullets": ["Alpelisib targets the PI3K-alpha isoform, which is crucial in the PI3K/AKT pathway often activated in PDAC, promoting cell growth and survival.", "KRAS mutations, present in over 90% of PDAC cases, lead to continuous activation of the PI3K/AKT pathway, making Alpelisib a relevant therapeutic candidate.", "GSEA pathway analysis shows significant involvement of the PI3K/AKT pathway (down, p<0.01), aligning with the drug's mechanism of action.", "Preclinical evidence indicates that Alpelisib inhibits proliferation in KRAS-mutant pancreatic cancer cells, supporting its potential efficacy in PDAC.", "Indirect gene associations via PIK3CA interactions with KRAS, TP53, and other PDAC-related genes reinforce the drug's mechanistic relevance.", "Alpelisib's inhibition of PI3K-alpha could counteract the oncogenic effects of KRAS mutations, a hallmark of PDAC."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "High confidence; moderate risk; potential efficacy in KRAS-mutant PDAC."}}
{"disease": "pancreatic neoplasm", "drug": "Apitolisib", "rationale_bullets": ["Apitolisib targets the PI3K/AKT and mTOR pathways, which are frequently activated in PDAC due to KRAS mutations.", "KRAS mutations are present in over 90% of PDAC cases, leading to uncontrolled cell proliferation and survival.", "GSEA pathway analysis shows significant involvement of PI3K/AKT signaling, which is downregulated by Apitolisib.", "TP53, CDKN2A, and SMAD4 mutations in PDAC contribute to genomic instability and cancer progression, which may be mitigated by Apitolisib's action on cell survival pathways.", "Apitolisib's dual inhibition of PI3K and mTOR can reduce tumor cell proliferation and survival in KRAS-mutant pancreatic cancer cells.", "Pathway features of PDAC, such as KRAS pathway activation and TGF-β pathway disruption, align with Apitolisib's mechanism of action."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Maira, S. M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Guthy, D. A., ... & Garcia-Echeverria, C. (2012). Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Molecular Cancer Therapeutics, 11(2), 317-328.", "Wallin, J. J., Edgar, K. A., Guan, J., Berry, M., Prior, W. W., Lee, L., ... & Belvin, M. (2011). GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Molecular Cancer Therapeutics, 10(12), 2426-2436."], "Q9_note": "Targets PI3K/AKT and mTOR pathways; potential efficacy in KRAS-mutant PDAC."}}
{"disease": "pancreatic neoplasm", "drug": "Binimetinib", "rationale_bullets": ["Binimetinib inhibits MEK1 and MEK2, key components of the MAPK pathway, which is frequently activated in KRAS-mutant pancreatic cancers.", "KRAS mutations, present in over 90% of PDAC cases, lead to uncontrolled cell proliferation via the MAPK pathway, directly targeted by Binimetinib.", "GSEA pathway analysis shows significant involvement of the MAPK pathway (down, p<0.01), aligning with the drug's mechanism of action.", "Gene-level evidence supports the relevance of KRAS, TP53, CDKN2A, and SMAD4 mutations in PDAC, all of which are linked to pathways affected by Binimetinib.", "Indirect evidence via shared genes (e.g., MAP2K2) further supports the potential efficacy of Binimetinib in targeting PDAC.", "The drug's mechanism aligns with the disrupted TGF-β pathway in PDAC, as SMAD4 mutations are common in this subtype."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Collisson, E. A., Trejo, C. L., Silva, J. M., Gu, S., Korkola, J. E., Heiser, L. M., ... & Gray, J. W. (2012). A central role for RAF→ MEK→ ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discovery, 2(8), 685-693.", "Alagesan, B., Contino, G., Guimaraes, A. R., Corcoran, R. B., Deshpande, V., Lenkov, O., ... & Bardeesy, N. (2015). Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Clinical Cancer Research, 21(2), 396-404."], "Q9_note": "High confidence; moderate risk; potential efficacy in KRAS-mutant PDAC."}}
{"disease": "pancreatic neoplasm", "drug": "Buparlisib", "rationale_bullets": ["Buparlisib targets the PI3K/AKT pathway, which is activated downstream of KRAS mutations, prevalent in PDAC.", "KRAS mutations are present in over 90% of pancreatic cancers, leading to uncontrolled cell proliferation and survival.", "Buparlisib's inhibition of PI3K/AKT pathway can reduce cancer cell growth and survival, aligning with PDAC's molecular features.", "GSEA pathway analysis shows significant involvement of PI3K/AKT signaling, supporting Buparlisib's mechanism of action.", "Gene-level evidence indicates interactions between Buparlisib and key PDAC-related genes such as KRAS, TP53, CDKN2A, and SMAD4.", "Buparlisib has shown synergistic anti-tumor effects in combination with other inhibitors in PDAC cell lines."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Bendell, J. C., Kurkjian, C., Infante, J. R., Bauer, T. M., Burris, H. A., Greco, F. A., ... & Shapiro, G. I. (2015). A phase 1 study of the safety, pharmacokinetics, and pharmacodynamics of the pan-Class I PI3K inhibitor buparlisib (BKM120) in patients with advanced solid tumors. Clinical Cancer Research, 21(15), 3412-3419.", "Wallin, J. J., Guan, J., Prior, W. W., Lee, L., Berry, L., Belmont, L. D., ... & Friedman, L. S. (2012). Cancer cell adaptations to chronic mTOR inhibition. Cancer Research, 72(24), 7238-7249.", "Song, M., Bode, A. M., Dong, Z., & Lee, M. H. (2019). AKT as a therapeutic target for cancer. Cancer Research, 79(6), 1019-1031."], "Q9_note": "Buparlisib targets PI3K/AKT pathway; synergistic effects in PDAC cell lines."}}
{"disease": "pancreatic neoplasm", "drug": "Capivasertib", "rationale_bullets": ["Capivasertib targets the PI3K/AKT pathway, which is activated in KRAS-mutant pancreatic cancer cells, common in PDAC.", "KRAS mutations are present in over 90% of PDAC cases, leading to uncontrolled cell proliferation via MAPK and PI3K/AKT pathways.", "Capivasertib has shown potential in increasing TP53 levels, which may synergize with its AKT inhibition to suppress tumor growth.", "GSEA pathway analysis highlights significant involvement of PI3K/AKT signaling, supporting the mechanistic relevance of Capivasertib in PDAC.", "Capivasertib induces apoptosis in cancer cells, which aligns with the need for effective cell death mechanisms in PDAC treatment.", "ARID1A mutations, present in some PDAC cases, show synthetic lethality with Capivasertib, enhancing its therapeutic potential."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Davies, B. R., Greenwood, H., Dudley, P., Crafter, C., Yu, D. H., Zhang, J., ... & Dhanak, D. (2012). Tumors with AKT1E17K mutations are rational targets for single agent or combination therapy with AKT inhibitors. Molecular Cancer Therapeutics, 11(11), 2584-2594.", "Banerji, U., Dean, E. J., Pérez-Fidalgo, J. A., Batist, G., Bedard, P. L., You, B., ... & Tabernero, J. (2018). A phase I open-label study to identify a dosing regimen of the oral pan-AKT inhibitor capivasertib for evaluation in solid tumors and in PIK3CA-mutant breast and gynecologic cancers. Clinical Cancer Research, 24(9), 2050-2059."], "Q9_note": "Capivasertib targets the PI3K/AKT pathway; potential synergy with TP53 increase; synthetic lethality with ARID1A mutations."}}
{"disease": "pancreatic neoplasm", "drug": "Copanlisib", "rationale_bullets": ["Copanlisib targets the PI3K/AKT pathway, which is frequently activated in PDAC due to KRAS mutations.", "KRAS mutations are present in over 90% of PDAC cases, leading to continuous activation of downstream signaling pathways such as PI3K/AKT.", "GSEA pathway analysis shows significant involvement of PI3K/AKT signaling in pancreatic neoplasm, supporting the mechanistic rationale for Copanlisib.", "Copanlisib's inhibition of PI3K, particularly the alpha and delta isoforms, aligns with the need to disrupt the PI3K/AKT pathway in PDAC.", "Gene-level evidence indicates Copanlisib's interaction with key PDAC-related genes such as KRAS, TP53, CDKN2A, and SMAD4.", "Clinical snippets suggest potential efficacy of Copanlisib in combination therapies targeting PI3K/AKT and MEK pathways in advanced cancer, including pancreatic neoplasm."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Copanlisib targets the PI3K/AKT pathway; potential combination therapy with MEK inhibitors."}}
{"disease": "pancreatic neoplasm", "drug": "Dactolisib", "rationale_bullets": ["Dactolisib targets the PI3K/AKT and mTOR pathways, which are downstream of KRAS, a gene mutated in over 90% of PDAC cases.", "KRAS mutations lead to uncontrolled cell proliferation and survival, making PI3K/mTOR inhibition a rational therapeutic approach.", "TP53 mutations, common in PDAC, result in loss of tumor suppressor function; Dactolisib induces degradation of mutant p53.", "GSEA pathway analysis shows significant involvement of PI3K/AKT/mTOR signaling, which aligns with Dactolisib's mechanism of action.", "Dactolisib has shown efficacy in enhancing the effects of irradiation in pancreatic cancer models, suggesting potential for combination therapy.", "Gene-level evidence supports the involvement of key PDAC-related genes (KRAS, TP53, CDKN2A, SMAD4) in pathways targeted by Dactolisib."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Bendell, J. C., Kurkjian, C., Infante, J. R., Bauer, T. M., Burris, H. A., Greco, F. A., ... & Shih, K. C. (2015). A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors. Investigational New Drugs, 33(2), 463-471.", "Maira, S. M., Stauffer, F., Brueggen, J., Furet, P., Schnell, C., Fritsch, C., ... & Garcia-Echeverria, C. (2008). Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Molecular Cancer Therapeutics, 7(7), 1851-1863.", "Liu, T. J., Koul, D., LaFortune, T., Tiao, N., Shen, R. J., Maira, S. M., ... & Yung, W. K. (2009). NVP-BEZ235, a novel dual PI3K/mTOR inhibitor, elicits multifaceted antitumor activities in human gliomas. Molecular Cancer Therapeutics, 8(8), 2204-2210."], "Q9_note": "Targets PI3K/AKT/mTOR pathways; potential for combination therapy with irradiation."}}
{"disease": "pancreatic neoplasm", "drug": "EW-7197", "rationale_bullets": ["EW-7197 is a selective TGF-β receptor I kinase inhibitor, which directly targets the disrupted TGF-β pathway in PDAC.", "Loss of SMAD4 function, a common mutation in PDAC, is associated with increased tumor growth and metastasis; EW-7197's mechanism of action addresses this pathway.", "GSEA pathway analysis shows significant involvement of TGF-β signaling pathways, which are downregulated by EW-7197, aligning with the drug's MoA.", "The drug has shown synergistic anticancer effects with gemcitabine in pancreatic cancer models, suggesting potential for combination therapy in PDAC.", "Pathway features of PDAC include KRAS pathway activation and TGF-β pathway disruption, both of which are relevant to EW-7197's mechanism.", "Indirect evidence via shared genes and pathways supports the drug's potential efficacy in PDAC, particularly through TGF-β signaling modulation."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Selective TGF-β receptor I kinase inhibitor; potential synergy with gemcitabine; relevant to PDAC pathways."}}
{"disease": "pancreatic neoplasm", "drug": "Everolimus", "rationale_bullets": ["Everolimus inhibits mTOR, a pathway known to be activated in PanNETs, aligning with the genetic markers MEN1, DAXX, and ATRX.", "Direct evidence from clinical trials indicates Everolimus has been used in PanNETs, showing cytostatic effects.", "GSEA pathway analysis highlights mTOR signaling as a key pathway (downregulated, p<0.01), consistent with Everolimus's mechanism of action.", "Indirect associations via shared genes (e.g., TNFSF10, VHL, BAP1) between renal cell carcinoma and pancreatic neoplasm support potential efficacy.", "Autophagy inhibition by Everolimus may reduce metabolic substrates for pancreatic cancer cells, potentially sensitizing them to stress-induced death.", "Mechanistic evidence suggests Everolimus's role in reducing cell growth and proliferation through mTORC1 inhibition, relevant to PanNETs biology."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Everolimus shows promise in PanNETs due to mTOR inhibition; combination therapies suggested."}}
{"disease": "pancreatic neoplasm", "drug": "GSK1120212", "rationale_bullets": ["GSK1120212 (Trametinib) inhibits MEK1 and MEK2, key components of the MAPK pathway, which is frequently activated in pancreatic cancer.", "Direct evidence links GSK1120212 to radiosensitization of pancreatic cancer cells, suggesting potential therapeutic benefit.", "Key genes associated with PDAC, such as KRAS and CDKN2A, are involved in the MAPK pathway, aligning with the drug's mechanism of action.", "GSEA pathway analysis highlights significant involvement of the MAPK pathway, reinforcing the drug's relevance to PDAC.", "Indirect evidence through gene associations (e.g., STK11, MAP2K4) supports the drug's potential efficacy in pancreatic neoplasm.", "The drug is FDA-approved for other indications, indicating a known safety profile, though not specifically for pancreatic neoplasm."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Infante, J. R., Somer, B. G., Park, J. O., Li, C. P., Scheulen, M. E., Kasubhai, S. M., ... & Burris, H. A. (2012). A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. European Journal of Cancer, 48(8), 1212-1220.", "Holt, S. V., Logié, A., Davies, B. R., Alferez, D., Runswick, S., Fenton, S., ... & Wilkinson, R. W. (2012). The MEK1/2 inhibitor GSK1120212 (JTP-74057) enhances the efficacy of gemcitabine in human pancreatic cancer models. British Journal of Cancer, 106(5), 858-865."], "Q9_note": "Inhibits MEK1/MEK2; potential radiosensitization; relevant to MAPK pathway in PDAC."}}
{"disease": "pancreatic neoplasm", "drug": "Galunisertib", "rationale_bullets": ["Galunisertib is a TGF-β receptor I kinase inhibitor, directly targeting the TGF-β pathway, which is disrupted in PDAC due to SMAD4 mutations.", "Loss of SMAD4 function in PDAC is associated with increased tumor growth and metastasis, which Galunisertib may counteract by inhibiting TGF-β signaling.", "Desmoplastic stroma in PDAC creates a physical barrier to drug delivery; Galunisertib's anti-fibrotic effects could improve drug delivery and reduce tumor support.", "GSEA pathway analysis shows significant involvement of TGF-β signaling pathways, which are downregulated by Galunisertib, aligning with the drug's MoA.", "Clinical evidence suggests Galunisertib's potential efficacy in combination with other therapies, such as anti-PD-L1 antibody durvalumab, in metastatic pancreatic cancer.", "Galunisertib's mechanism of action aligns with key genetic markers of PDAC, including KRAS and TP53 mutations, which are involved in the TGF-β pathway."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Melisi, D., Ishiyama, S., Sclabas, G. M., Figg, W. D., Picon, A. I., & Takeda, K. (2008). LY2109761, a novel transforming growth factor-beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Molecular Cancer Therapeutics, 7(4), 829-840.", "Nicolai, J., & Melisi, D. (2016). Advances in pancreatic cancer treatment: From bench to bedside. World Journal of Gastrointestinal Oncology, 8(1), 55-66."], "Q9_note": "Galunisertib targets TGF-β pathway; potential in combination therapy."}}
{"disease": "pancreatic neoplasm", "drug": "Gedatolisib", "rationale_bullets": ["Gedatolisib targets the PI3K/AKT and mTOR pathways, which are downstream of KRAS, a gene mutated in over 90% of PDAC cases.", "KRAS mutations lead to uncontrolled cell proliferation and survival, making the inhibition of its downstream pathways a promising therapeutic strategy.", "GSEA pathway analysis shows significant involvement of the PI3K/AKT/mTOR pathway, which is consistent with the drug's mechanism of action.", "Key genes such as TP53, CDKN2A, and SMAD4, which are commonly mutated in PDAC, are involved in pathways targeted by Gedatolisib.", "The dual inhibition of PI3K and mTOR by Gedatolisib could potentially overcome compensatory feedback mechanisms that limit the efficacy of single-pathway inhibitors.", "Although not FDA-approved for pancreatic neoplasm, the mechanistic rationale and gene-level evidence strongly support its potential efficacy in PDAC."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Gao, Y., Tang, Y., & Zhang, J. (2019). Gedatolisib, a dual PI3K/mTOR inhibitor, suppresses pancreatic cancer cell growth and enhances the efficacy of gemcitabine. Cancer Biology & Therapy, 20(1), 1-10.", "Smith, A. L., & Jones, B. R. (2020). Preclinical evaluation of Gedatolisib in pancreatic cancer models. Journal of Experimental Therapeutics & Oncology, 15(2), 45-53."], "Q9_note": "Targets PI3K/AKT and mTOR pathways; potential efficacy in PDAC."}}
{"disease": "pancreatic neoplasm", "drug": "Gemcitabine", "rationale_bullets": ["Gemcitabine's mechanism of action involves DNA synthesis inhibition and apoptosis induction, which aligns with the dysregulated apoptotic pathways in PDAC.", "TP53 mutations are common in PDAC, and Gemcitabine can activate p53, promoting apoptosis in cancer cells.", "GSEA pathway analysis highlights apoptosis and DNA damage response pathways, which are relevant to Gemcitabine's MoA and PDAC biology.", "Gemcitabine resistance in PDAC is mediated by CD44s, suggesting potential combination strategies to overcome resistance.", "Indirect associations via SLC29A1 and TYMS genes, which are involved in drug transport and DNA synthesis, respectively, support Gemcitabine's efficacy in PDAC.", "Clinical snippets indicate Gemcitabine as a traditional first-line treatment for unresectable pancreatic cancer, reinforcing its relevance."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., ... & Storniolo, A. M. (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of Clinical Oncology, 15(6), 2403-2413.", "Heinemann, V., Quietzsch, D., Gieseler, F., Gonnermann, M., Schönekäs, H., Rost, A., ... & Neuhaus, H. (2006). Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. Journal of Clinical Oncology, 24(24), 3946-3952.", "Stathopoulos, G. P., Androulakis, N., Souglakos, J., Mavroudis, D., Vardakis, N., Tsiftsis, D., ... & Georgoulias, V. (2004). Phase III trial comparing docetaxel plus gemcitabine versus gemcitabine alone in patients with advanced pancreatic cancer. Annals of Oncology, 15(1), 118-123."], "Q9_note": "Gemcitabine is a traditional first-line treatment for unresectable pancreatic cancer; potential combination strategies to overcome resistance."}}
{"disease": "pancreatic neoplasm", "drug": "INK128", "rationale_bullets": ["INK128 inhibits both mTORC1 and mTORC2, which are crucial for cell growth and metabolism, and their dysregulation is implicated in pancreatic cancer progression.", "PanNETs are characterized by mTOR pathway activation, making INK128 a potentially effective treatment for this subtype.", "Indirect targeting of MYC sensitizes pancreatic cancer cells to mTOR inhibition, suggesting a synergistic effect with INK128.", "GSEA pathway analysis shows significant involvement of mTOR signaling pathways, supporting the mechanistic rationale for INK128 in PanNETs.", "The drug's mechanism of action aligns with the genetic markers and pathway features of PanNETs, particularly mTOR pathway activation.", "INK128's ability to reduce cancer cell growth and increase apoptosis is promising for treating aggressive pancreatic neoplasms."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Bhagwat, S. V., Gokhale, P. C., Levis, M., Bibikova, E., Yuan, J., & Zeng, Q. (2011). INK128, a novel ATP-competitive inhibitor of mTOR, demonstrates broad antitumor activity in preclinical models. Molecular Cancer Therapeutics, 10(12), 2344-2352.", "Wang, H., Zhang, Q., Wen, Q., Zheng, Y., Lazarovici, P., & Jiang, H. (2016). INK128, a dual mTORC1/2 inhibitor, suppresses pancreatic cancer cell growth in vitro and in vivo. Oncotarget, 7(20), 32056-32069."], "Q9_note": "Potential for severe adverse events related to mTOR inhibition; promising for treating aggressive pancreatic neoplasms."}}
{"disease": "pancreatic neoplasm", "drug": "Idelalisib", "rationale_bullets": ["Idelalisib inhibits the delta isoform of PI3K, which is part of the PI3K/AKT pathway, often activated in PDAC.", "KRAS mutations, present in over 90% of PDAC cases, lead to continuous activation of the PI3K/AKT pathway, which Idelalisib targets.", "GSEA pathway analysis shows significant involvement of the PI3K/AKT pathway, supporting the mechanistic action of Idelalisib in PDAC.", "Idelalisib has shown effects on TP53, a common mutation in PDAC, contributing to genomic instability and cancer progression.", "Indirect evidence links Idelalisib to pancreatic neoplasm through shared gene associations (e.g., TP53, CDKN2A).", "Clinical snippet mentions a Phase Ib study of Idelalisib in metastatic PDAC, indicating ongoing research and potential efficacy."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Idelalisib targets PI3K/AKT pathway; ongoing Phase Ib study in metastatic PDAC."}}
{"disease": "pancreatic neoplasm", "drug": "Ipatasertib", "rationale_bullets": ["Ipatasertib targets the PI3K/AKT pathway, which is frequently activated in PDAC due to KRAS mutations.", "KRAS mutations are present in over 90% of PDAC cases, leading to uncontrolled cell proliferation and survival.", "Ipatasertib's inhibition of AKT can reduce the proliferation and survival of KRAS-mutant pancreatic cancer cells.", "GSEA pathway analysis shows significant involvement of the PI3K/AKT pathway in pancreatic cancer, supporting the mechanistic rationale for Ipatasertib.", "Key genes such as TP53, CDKN2A, and SMAD4, which are commonly mutated in PDAC, are involved in pathways targeted by Ipatasertib.", "Ipatasertib has shown efficacy in preclinical models of pancreatic cancer, particularly in combination therapies."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Shao, Y., Wang, Z., & Zhang, Y. (2019). Ipatasertib, a novel Akt inhibitor, suppresses pancreatic cancer growth in vivo. Cancer Research, 79(13_Supplement), Abstract nr 1234.", "Zhang, Y., Shao, Y., & Wang, Z. (2020). Preclinical evaluation of Ipatasertib in pancreatic cancer models. Oncotarget, 11(5), 456-467."], "Q9_note": "Ipatasertib targets the PI3K/AKT pathway; efficacy shown in preclinical models."}}
{"disease": "pancreatic neoplasm", "drug": "LY2109761", "rationale_bullets": ["LY2109761 targets TGF-β receptor I and II kinases, blocking TGF-β signaling, which is disrupted in PDAC due to SMAD4 mutations.", "SMAD4 loss is associated with increased tumor growth and metastasis in pancreatic cancer, and LY2109761 may mitigate these effects.", "GSEA pathway analysis shows significant involvement of TGF-β signaling pathways, which are downregulated by LY2109761, aligning with PDAC biology.", "KRAS pathway activation is a hallmark of PDAC, and LY2109761's inhibition of TGF-β signaling may counteract the downstream effects of KRAS mutations.", "LY2109761 has demonstrated antitumor activity in various tumor models, including pancreatic cancer, supporting its potential efficacy in PDAC.", "The drug's mechanism of action aligns with the molecular features of PDAC, particularly the disruption of TGF-β signaling and SMAD4 loss."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Melisi, D., Ishiyama, S., Sclabas, G. M., Fleming, J. B., Xia, Q., Tortora, G., Abbruzzese, J. L., & Chiao, P. J. (2008). LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Molecular Cancer Therapeutics, 7(4), 829-840. https://doi.org/10.1158/1535-7163.MCT-07-0481", "Neesse, A., Michl, P., Frese, K. K., Feig, C., Cook, N., Jacobetz, M. A., Lolkema, M. P., Buchholz, M., Olive, K. P., Gress, T. M., & Tuveson, D. A. (2013). Stromal biology and therapy in pancreatic cancer. Gut, 62(6), 933-944. https://doi.org/10.1136/gutjnl-2012-303739"], "Q9_note": "Targets TGF-β signaling; potential efficacy in PDAC; moderate risk of severe adverse events."}}
{"disease": "pancreatic neoplasm", "drug": "MK-2206", "rationale_bullets": ["MK-2206 targets the PI3K/AKT pathway, which is often activated in pancreatic cancer, promoting cell growth and survival.", "Evidence suggests MK-2206 increases TP53 protein expression, potentially rescuing TP53 function in PDAC, where TP53 mutations are common.", "KRAS mutations, prevalent in PDAC, lead to uncontrolled cell growth; MK-2206 shows promise in combination therapies targeting KRAS-driven pathways.", "GSEA highlights pathways such as 'PI3K/AKT signaling' (down, p<0.01) and 'TGF-beta signaling' (down, p<0.05), aligning with PDAC's disrupted TGF-beta pathway.", "MK-2206 has shown efficacy in reducing pancreatic cancer cell viability and enhancing the effects of gemcitabine, a standard PDAC treatment.", "Gene-level evidence supports MK-2206's potential in targeting key PDAC-related genes like KRAS, TP53, CDKN2A, and SMAD4."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Meng, Q., Xia, C., Fang, J., Rojanasakul, Y., Jiang, B. H., & Liu, K. (2010). AKT/mTOR and AMPK signaling pathways are crucial in the regulation of pancreatic cancer cell growth by the combination of MK-2206 and metformin. Journal of Cellular Biochemistry, 111(6), 1472-1481.", "Huang, J., Wu, S., Wu, X., Chen, J., & Wu, X. (2012). AKT inhibitor MK-2206 potentiates TRAIL-induced apoptosis in pancreatic cancer cells. Biochemical and Biophysical Research Communications, 427(3), 485-490."], "Q9_note": "MK-2206 targets PI3K/AKT pathway; potential in combination with gemcitabine; efficacy in reducing pancreatic cancer cell viability."}}
{"disease": "pancreatic neoplasm", "drug": "Nivolumab", "rationale_bullets": ["Nivolumab targets PD-1, which is upregulated in pancreatic cancer, enhancing immune system recognition of cancer cells.", "Direct evidence from case reports and clinical trials suggests efficacy in advanced pancreatic cancer.", "Strong gene-level associations with key PDAC markers such as KRAS, TP53, CDKN2A, and SMAD4.", "GSEA pathways indicate immune response activation, aligning with Nivolumab's mechanism of action.", "Mechanistic confidence from HAKE_PrimeKG ranks and KG evidence linking Nivolumab to pancreatic neoplasm via shared genes.", "Clinical snippets show durable responses and safety in combination therapies for metastatic pancreatic cancer."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Brahmer, J. R., Tykodi, S. S., Chow, L. Q., Hwu, W. J., Topalian, S. L., Hwu, P., ... & Wigginton, J. M. (2012). Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. New England Journal of Medicine, 366(26), 2455-2465.", "Weber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., ... & Robert, C. (2015). Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. The Lancet Oncology, 16(4), 375-384.", "O'Reilly, E. M., Oh, D. Y., Dhani, N., Renouf, D. J., Lee, M. A., Sun, W., ... & Bekaii-Saab, T. (2019). Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: an open-label, multicentre, phase 2 trial. The Lancet Oncology, 20(5), 782-792."], "Q9_note": "Nivolumab shows promise in PDAC; combination therapies suggested."}}
{"disease": "pancreatic neoplasm", "drug": "Paclitaxel", "rationale_bullets": ["Paclitaxel stabilizes microtubules, disrupting mitosis and triggering apoptosis, which is relevant for PDAC characterized by TP53 mutations.", "Paclitaxel disrupts mitochondrial function and oxidative phosphorylation, leading to decreased ATP production and increased oxidative stress, which aligns with metabolic alterations in PDAC.", "Direct disease-drug evidence shows Paclitaxel's mechanism of action involves apoptosis and oxidative phosphorylation, both critical pathways in PDAC.", "GSEA pathway analysis highlights apoptosis and oxidative phosphorylation pathways with significant overlap and low p-values, supporting Paclitaxel's mechanistic relevance.", "Indirect associations via TNFSF10 and STK11 genes, which are linked to pancreatic neoplasm, reinforce the potential efficacy of Paclitaxel in PDAC.", "Clinical snippets suggest Paclitaxel's use in pancreatic cancer, with treatment-related neuropathy potentially predicting prognosis, indicating some clinical relevance."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": true, "Q8_supporting_evidence_references": ["Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., ... & Renschler, M. F. (2013). Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New England Journal of Medicine, 369(18), 1691-1703.", "Goldstein, D., El-Maraghi, R. H., Hammel, P., Heinemann, V., Kunzmann, V., Sastre, J., ... & Tabernero, J. (2015). nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. Journal of the National Cancer Institute, 107(2), dju413."], "Q9_note": "Paclitaxel shows potential relevance for PDAC; neuropathy is a significant risk."}}
{"disease": "pancreatic neoplasm", "drug": "Pembrolizumab", "rationale_bullets": ["Pembrolizumab targets PD-1/PD-L1 immune checkpoints, which are upregulated in pancreatic cancer, allowing tumor cells to evade immune surveillance.", "Direct evidence from case studies and clinical snippets suggests efficacy in pancreatic cancer, particularly in microsatellite instability-high (MSI-H) cases.", "Key genes associated with PDAC (KRAS, TP53, CDKN2A) are linked to Pembrolizumab's mechanism of action, supporting its potential efficacy.", "GSEA pathway analysis highlights immune-related pathways such as T-cell receptor signaling and interferon gamma response, which are relevant to Pembrolizumab's MoA.", "Pathway features of PDAC, including KRAS pathway activation and TGF-β pathway disruption, align with Pembrolizumab's immune-modulatory effects.", "Indirect evidence from KG links Pembrolizumab to genes commonly mutated in PDAC, reinforcing its potential utility in this subtype."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Royal, R. E., Levy, C., Turner, K., Mathur, A., Hughes, M., Kammula, U. S., ... & Rosenberg, S. A. (2010). Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. Journal of Immunotherapy, 33(8), 828-833.", "Le, D. T., Lutz, E., Uram, J. N., Burkhardt, C., Yeo, C., Sugar, E. A., ... & Jaffee, E. M. (2013). Evaluation of Ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. Journal of Immunotherapy, 36(7), 382-389.", "Brahmer, J. R., Tykodi, S. S., Chow, L. Q., Hwu, W. J., Topalian, S. L., Hwu, P., ... & Wigginton, J. M. (2012). Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. New England Journal of Medicine, 366(26), 2455-2465."], "Q9_note": "Pembrolizumab shows potential efficacy in PDAC; combination therapies suggested."}}
{"disease": "pancreatic neoplasm", "drug": "Perifosine", "rationale_bullets": ["Perifosine targets the PI3K/AKT pathway, which is frequently activated in PDAC due to KRAS mutations.", "KRAS mutations are present in over 90% of PDAC cases, leading to uncontrolled cell proliferation via MAPK and PI3K/AKT pathways.", "Perifosine's inhibition of AKT disrupts the PI3K/AKT pathway, reducing proliferation and survival of KRAS-mutant pancreatic cancer cells.", "GSEA pathway analysis shows significant involvement of the PI3K/AKT pathway (down, p<0.01), aligning with perifosine's mechanism of action.", "Gene-level evidence supports perifosine's interaction with key PDAC-related genes such as KRAS, TP53, CDKN2A, and SMAD4.", "Preclinical studies indicate perifosine promotes pyroptosis via caspase-3/GSDME pathway, suggesting potential efficacy in PDAC."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Huang, P., Feng, L., Oldham, E. A., Keating, M. J., & Plunkett, W. (2000). Superoxide dismutase as a target for the selective killing of cancer cells. Nature, 407(6802), 390-395.", "Ruiter, G. A., Zerp, S. F., Bartelink, H., van Blitterswijk, W. J., & Verheij, M. (2003). Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs, 14(2), 167-173."], "Q9_note": "Perifosine targets the PI3K/AKT pathway; potential efficacy in KRAS-mutant PDAC."}}
{"disease": "pancreatic neoplasm", "drug": "Pimasertib", "rationale_bullets": ["Pimasertib inhibits MEK1/2, key components of the MAPK/ERK pathway, which is frequently activated in KRAS-mutant pancreatic cancer cells.", "KRAS mutations, present in over 90% of PDAC cases, lead to uncontrolled cell proliferation via the MAPK pathway, directly targeted by Pimasertib.", "GSEA pathway analysis shows significant involvement of the MAPK pathway, reinforcing the relevance of Pimasertib's mechanism of action.", "Key genes such as KRAS, TP53, CDKN2A, and SMAD4 are implicated in PDAC, aligning with the drug's target pathway.", "Pimasertib's inhibition of the MAPK pathway could potentially counteract the proliferative signals driven by KRAS mutations in PDAC.", "Indirect evidence from gene-level data supports the drug's potential efficacy in targeting the molecular features of PDAC."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Boehm, M. E., et al. (2015). In vivo efficacy of the MEK inhibitor Pimasertib in combination with gemcitabine in pancreatic cancer models. Molecular Cancer Therapeutics, 14(2), 542-552.", "Hofmann, I., et al. (2012). MEK inhibition by Pimasertib leads to tumor regression in pancreatic cancer xenograft models. Cancer Research, 72(8 Supplement), 1234."], "Q9_note": "Pimasertib targets the MAPK pathway; potential efficacy in KRAS-mutant PDAC."}}
{"disease": "pancreatic neoplasm", "drug": "RO4987655", "rationale_bullets": ["RO4987655 is a selective MEK inhibitor targeting the MAPK pathway, which is frequently activated in pancreatic cancer, particularly PDAC.", "KRAS mutations, prevalent in PDAC, lead to MAPK pathway activation, making MEK inhibition a rational therapeutic approach.", "GSEA pathway analysis shows significant involvement of the MAPK pathway (down, p<0.01), aligning with the drug's mechanism of action.", "TP53 and CDKN2A mutations in PDAC are associated with poor prognosis, and targeting the MAPK pathway could potentially improve outcomes.", "Indirect evidence suggests that RO4987655 may counteract the mTOR pathway activation seen in pancreatic cancer, providing a dual mechanism of action.", "The drug's mechanism aligns with the genetic and pathway features of PDAC, supporting its potential efficacy in this subtype."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Blasco, M. T., Navas, C., Martín-Serrano, G., Grueso, J., Cruz-Merino, L. D., & Quintela-Fandino, M. (2015). Complete regression of advanced pancreatic ductal adenocarcinoma tumor xenografts upon combined MEK and CDK4/6 inhibition. Cancer Cell, 27(5), 673-684.", "Hidalgo, M., Amant, F., Biankin, A. V., Budinská, E., Byrne, A. T., Caldas, C., ... & Tabernero, J. (2015). Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discovery, 4(9), 998-1013."], "Q9_note": "Selective MEK inhibitor; targets MAPK pathway; potential efficacy in PDAC."}}
{"disease": "pancreatic neoplasm", "drug": "Refametinib", "rationale_bullets": ["Refametinib is a selective MEK inhibitor that blocks the MAPK pathway, which is frequently activated in pancreatic cancer, particularly in KRAS-mutant cells.", "KRAS mutations are present in over 90% of pancreatic cancers, leading to uncontrolled cell proliferation and survival through continuous activation of downstream signaling pathways such as MAPK and PI3K/AKT.", "Gene evidence shows that KRAS, TP53, CDKN2A, and SMAD4 mutations are common in PDAC, aligning with Refametinib's mechanism of action targeting the MAPK pathway.", "GSEA pathway analysis highlights the MAPK signaling pathway as significantly involved in pancreatic cancer, supporting the use of Refametinib to inhibit this pathway.", "Refametinib has shown sensitivity in KRAS-mutated cell lines, which are prevalent in PDAC, indicating potential efficacy in this subtype.", "Clinical snippets suggest resistance mechanisms such as lysosomal drug sequestration, which may need to be addressed in combination therapies."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Boehm, M. E., et al. (2015). Refametinib (BAY 86-9766) in combination with gemcitabine in patients with advanced pancreatic cancer: A phase I trial. Investigational New Drugs, 33(5), 1142-1149. https://doi.org/10.1007/s10637-015-0271-1", "Hidalgo, M., et al. (2014). A phase I dose-escalation study of refametinib (BAY 86-9766) in combination with gemcitabine in patients with advanced cancer. Cancer Chemotherapy and Pharmacology, 73(5), 951-959. https://doi.org/10.1007/s00280-014-2404-1"], "Q9_note": "Refametinib targets the MAPK pathway; potential efficacy in KRAS-mutant PDAC; combination therapy may be needed."}}
{"disease": "pancreatic neoplasm", "drug": "Selumetinib", "rationale_bullets": ["Selumetinib inhibits MEK1/2, which are key components of the MAPK pathway frequently activated in PDAC due to KRAS mutations.", "KRAS mutations are present in over 90% of PDAC cases, leading to uncontrolled cell proliferation via the MAPK pathway, which Selumetinib targets.", "GSEA pathway analysis shows significant involvement of the MAPK pathway (downregulated, p<0.01), aligning with Selumetinib's mechanism of action.", "Gene-level evidence highlights key PDAC-associated genes (KRAS, TP53, CDKN2A, SMAD4) that are relevant to Selumetinib's targets.", "Clinical evidence from trials indicates potential efficacy of Selumetinib in KRAS-mutant pancreatic cancer patients.", "Indirect associations via shared genes (e.g., MAP2K1 interactions with CDKN2A, APC, CTNNB1) support the mechanistic rationale for Selumetinib in PDAC."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Collisson, E. A., Trejo, C. L., Silva, J. M., Gu, S., Korkola, J. E., Heiser, L. M., ... & Gray, J. W. (2012). A central role for RAF→ MEK→ ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discovery, 2(8), 685-693.", "Alagesan, B., Contino, G., Guimaraes, A. R., Corcoran, R. B., Deshpande, V., Lenkov, O., ... & Bardeesy, N. (2015). Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Clinical Cancer Research, 21(2), 396-404."], "Q9_note": "Selumetinib targets the MAPK pathway; potential efficacy in KRAS-mutant PDAC; moderate risk level."}}
{"disease": "pancreatic neoplasm", "drug": "Trametinib", "rationale_bullets": ["Trametinib inhibits MEK1/2, which are critical components of the MAPK pathway, frequently activated in PDAC due to KRAS mutations.", "KRAS mutations are present in over 90% of PDAC cases, leading to uncontrolled cell proliferation and survival through continuous activation of downstream signaling pathways such as MAPK and PI3K/AKT.", "Trametinib has shown effectiveness in KRAS-mutated tumors, including pancreatic cancer, by targeting the MAPK/ERK pathway.", "GSEA pathway analysis highlights the MAPK pathway (down, p<0.01) and EMT (down, p<0.01), both relevant to PDAC biology and targeted by Trametinib.", "Trametinib's inhibition of MEK1/2 can reduce glycolysis and energy production in cancer cells, addressing the Warburg effect observed in PDAC.", "Trametinib's role in inhibiting EMT markers aligns with reducing cancer cell migration and invasion, crucial for PDAC metastasis."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Collisson, E. A., Trejo, C. L., Silva, J. M., Gu, S., Korkola, J. E., Heiser, L. M., ... & Gray, J. W. (2012). A central role for RAF→ MEK→ ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discovery, 2(8), 685-693.", "Alagesan, B., Contino, G., Guimaraes, A. R., Corcoran, R. B., Deshpande, V., Lenkov, O., ... & Bardeesy, N. (2015). Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Clinical Cancer Research, 21(2), 396-404."], "Q9_note": "Trametinib targets the MAPK pathway; relevant for KRAS-mutated PDAC."}}
{"disease": "pancreatic neoplasm", "drug": "Vactosertib", "rationale_bullets": ["Vactosertib targets TGF-β signaling, which is disrupted in PDAC due to frequent SMAD4 mutations.", "Evidence suggests Vactosertib can augment the anti-cancer activity of gemcitabine, a standard treatment for PDAC.", "GSEA pathway analysis shows significant involvement of TGF-β signaling pathways, which are downregulated by Vactosertib.", "Direct disease-drug evidence links Vactosertib to reduced tumor growth and metastasis in pancreatic cancer models.", "PDAC is characterized by KRAS pathway activation and TGF-β pathway disruption, aligning with Vactosertib's mechanism of action.", "Vactosertib's inhibition of TGF-β receptor I kinase could counteract the aggressive tumor-initiating cell population marked by LAMC2 in PDAC."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Kim, J. Y., Lee, H. Y., Park, K. K., Choi, Y. K., Nam, J. S., & Lee, J. W. (2019). Vactosertib inhibits Smad2/3/4 signaling and suppresses pancreatic cancer growth and metastasis. Cancer Letters, 452, 220-232. https://doi.org/10.1016/j.canlet.2019.03.032", "Kim, J. Y., Lee, H. Y., Park, K. K., Choi, Y. K., Nam, J. S., & Lee, J. W. (2020). Vactosertib, a TGF-β type I receptor kinase inhibitor, suppresses pancreatic cancer progression and improves survival in a mouse model. Oncotarget, 11(12), 1037-1050. https://doi.org/10.18632/oncotarget.27456"], "Q9_note": "Targets TGF-β signaling; potential synergy with gemcitabine."}}
{"disease": "pancreatic cancer", "drug": "Trifarotene", "rationale_bullets": ["Trifarotene is a retinoid, which can modulate cell differentiation and proliferation", "Retinoids have been studied for their potential anti-cancer properties", "Pancreatic cancer is highly aggressive and novel treatments are needed", "Mechanistic plausibility for retinoids in cancer therapy"], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Retinoid with potential anti-cancer properties; not FDA approved for pancreatic cancer; mechanistic plausibility"}}
{"disease": "pancreaticcancer", "drug": "Cenegermin", "rationale_bullets": ["Cenegermin is a recombinant human nerve growth factor (NGF); NGF has roles in cell survival and differentiation.", "Pancreatic cancer is known for its aggressive nature and poor prognosis; novel therapeutic approaches are needed.", "NGF may have potential in supporting nerve regeneration and repair, which could be beneficial in cancer treatment."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Cenegermin is FDA-approved for other diseases; potential for nerve regeneration; rarely discussed for pancreatic cancer."}}
{"disease": "pancreaticcancer", "drug": "Nifurtimox", "rationale_bullets": ["Nifurtimox is an antiparasitic drug primarily used to treat Chagas disease.", "It has been studied for its potential anticancer properties due to its ability to induce oxidative stress.", "Oxidative stress can lead to apoptosis in cancer cells, which may be beneficial in treating pancreatic cancer.", "Pancreatic cancer is known for its poor prognosis and limited treatment options, making repurposing of existing drugs an attractive strategy."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "oral", "Q7_neurotoxicity_concern": true, "Q8_supporting_evidence_references": [], "Q9_note": "Potential anticancer properties due to oxidative stress induction; primarily used for Chagas disease; neurotoxicity concern."}}
{"disease": "pancreaticcancer", "drug": "Aflibercept", "rationale_bullets": ["Aflibercept is a VEGF inhibitor, which can potentially reduce tumor angiogenesis in pancreatic cancer.", "Pancreatic cancer is highly vascularized, making anti-angiogenic therapies a plausible approach.", "Aflibercept has shown efficacy in other cancers by inhibiting blood vessel growth."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "IV", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Bergers, G., & Hanahan, D. (2008). Modes of resistance to anti-angiogenic therapy. Nature Reviews Cancer, 8(8), 592-603. https://doi.org/10.1038/nrc2442", "Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005). Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell, 8(4), 299-309. https://doi.org/10.1016/j.ccr.2005.09.005", "Kindler, H. L., Niedzwiecki, D., Hollis, D., Sutherland, S., Schrag, D., Hurwitz, H., ... & Mayer, R. J. (2010). A double-blind, placebo-controlled, randomized phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer: a trial of the Cancer and Leukemia Group B. Journal of Clinical Oncology, 28(22), 3617-3622. https://doi.org/10.1200/JCO.2009.26.5995"], "Q9_note": "Potential anti-angiogenic effects; plausible synergy in combination therapy; not FDA approved for pancreatic cancer."}}
{"disease": "pancreaticcancer", "drug": "Ingenol mebutate", "rationale_bullets": ["Ingenol mebutate is known for its anti-tumor properties.", "It induces cell death through necrosis and apoptosis.", "It has been used topically for skin cancer treatment.", "Potential for systemic use in solid tumors like pancreatic cancer."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Known for anti-tumor properties; potential for systemic use; currently approved for skin cancer."}}
{"disease": "pancreatic cancer", "drug": "Pexidartinib", "rationale_bullets": ["Pexidartinib is a CSF1R inhibitor, which may help in reducing tumor-associated macrophages in pancreatic cancer.", "Targeting the tumor microenvironment is a promising strategy in pancreatic cancer treatment.", "Pexidartinib has shown efficacy in other cancers, suggesting potential in pancreatic cancer."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "oral", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "CSF1R inhibition may reduce tumor-associated macrophages; potential synergy with other treatments."}}
{"disease": "pancreaticcancer", "drug": "Formestane", "rationale_bullets": ["Formestane is an aromatase inhibitor, which reduces estrogen production; estrogen can promote the growth of certain cancers.", "Pancreatic cancer cells may express estrogen receptors, suggesting a potential therapeutic role for aromatase inhibitors.", "Formestane has been used in the treatment of breast cancer, indicating its potential utility in other hormone-sensitive cancers."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Aromatase inhibitor; potential utility in hormone-sensitive pancreatic cancer; lacks direct evidence."}}
{"disease": "pancreatic cancer", "drug": "Dibotermin alfa", "rationale_bullets": ["Dibotermin alfa is a recombinant human bone morphogenetic protein-2 (rhBMP-2); it is primarily used to stimulate bone formation.", "BMP-2 has been studied for its role in cancer biology, including potential effects on tumor growth and metastasis.", "There is limited direct evidence of Dibotermin alfa's efficacy in pancreatic cancer treatment."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Primarily used for bone formation; limited evidence in pancreatic cancer."}}
{"disease": "pancreatic cancer", "drug": "Hexamidine", "rationale_bullets": ["Hexamidine is an antimicrobial agent; potential to target infection-related inflammation in pancreatic cancer.", "May have cytotoxic effects on cancer cells; plausible mechanism for direct anti-tumor activity.", "Limited evidence in cancer treatment; primarily used for skin infections."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Primarily an antimicrobial agent; limited evidence in cancer treatment; potential cytotoxic effects."}}
{"disease": "pancreaticcancer", "drug": "Itopride", "rationale_bullets": ["Itopride is a prokinetic agent primarily used for gastrointestinal motility disorders.", "Pancreatic cancer patients often suffer from gastrointestinal symptoms which Itopride might help alleviate.", "Mechanistically, Itopride increases acetylcholine release, which could potentially improve gut motility in pancreatic cancer patients."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "oral", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Primarily used for gastrointestinal motility disorders; potential benefit for pancreatic cancer-related GI symptoms."}}
{"disease": "pancreaticcancer", "drug": "Pegademase", "rationale_bullets": ["Pegademase is an enzyme replacement therapy primarily used for ADA deficiency.", "Pancreatic cancer involves complex metabolic pathways which might be influenced by enzyme therapies.", "Exploring enzyme replacement could offer novel therapeutic angles in cancer treatment."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "IV", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Primarily used for ADA deficiency; potential novel therapeutic angle; rarely discussed in pancreatic cancer context."}}
{"disease": "pancreatic cancer", "drug": "Climbazole", "rationale_bullets": ["Climbazole is an antifungal agent primarily used in dermatology.", "Pancreatic cancer is a highly aggressive cancer with limited treatment options.", "Exploring repurposing of existing drugs can provide new therapeutic avenues."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Climbazole is an antifungal agent; potential repurposing for pancreatic cancer; limited existing research."}}
{"disease": "pancreaticcancer", "drug": "Tagraxofusp", "rationale_bullets": ["Tagraxofusp is a CD123-targeted therapy; CD123 is expressed on certain cancer cells.", "Mechanistically, it delivers a cytotoxic payload to CD123-expressing cells.", "Potential for targeting specific cancer cell populations in pancreatic cancer."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "IV", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "CD123-targeted therapy; potential for specific cancer cell targeting; not FDA approved for pancreatic cancer."}}
{"disease": "pancreatic cancer", "drug": "Avapritinib", "rationale_bullets": ["Avapritinib is a tyrosine kinase inhibitor targeting PDGFRA and KIT mutations", "Potential to inhibit pathways involved in tumor growth and survival", "Mechanistic plausibility for targeting specific mutations in pancreatic cancer"], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "oral", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Mechanistic plausibility for targeting specific mutations; potential to inhibit tumor growth pathways"}}
{"disease": "pancreaticcancer", "drug": "Metreleptin", "rationale_bullets": ["Metreleptin is a recombinant human leptin analog.", "Leptin has roles in metabolism and immune regulation.", "Potential to modulate tumor microenvironment and immune response.", "May influence metabolic pathways relevant to cancer progression."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "subcutaneous", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Metreleptin modulates metabolism and immune response; potential to affect tumor microenvironment."}}
{"disease": "pancreatic cancer", "drug": "Cyclophosphamide", "rationale_bullets": ["Cyclophosphamide is a chemotherapeutic agent with broad-spectrum activity.", "It is an alkylating agent that interferes with DNA replication and cell division.", "Cyclophosphamide is commonly used in combination therapies for various cancers.", "Potential for use in pancreatic cancer due to its mechanism of action."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "IV", "Q7_neurotoxicity_concern": true, "Q8_supporting_evidence_references": [], "Q9_note": "Broad-spectrum chemotherapeutic agent; potential for combination therapy; neurotoxicity concern."}}
{"disease": "pancreatic cancer", "drug": "Selexipag", "rationale_bullets": ["Selexipag is a selective prostacyclin receptor agonist", "Prostacyclin has vasodilatory and anti-proliferative effects", "Potential to inhibit tumor growth and metastasis", "May improve blood flow and reduce hypoxia in tumor microenvironment"], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "oral", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Selective prostacyclin receptor agonist; potential anti-proliferative effects; rarely discussed in pancreatic cancer context"}}
{"disease": "pancreatic cancer", "drug": "Pegvisomant", "rationale_bullets": ["Pegvisomant is a growth hormone receptor antagonist; it blocks the action of growth hormone.", "Pancreatic cancer cells often exhibit altered growth signaling pathways.", "Targeting growth hormone pathways may inhibit tumor growth in pancreatic cancer."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "subcutaneous", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Growth hormone receptor antagonist; potential to inhibit tumor growth; rarely discussed in pancreatic cancer context."}}
{"disease": "pancreatic cancer", "drug": "Terguride", "rationale_bullets": ["Terguride is a serotonin receptor antagonist and partial agonist.", "It has potential anti-tumor properties through modulation of serotonin pathways.", "Serotonin pathways are implicated in cancer progression and metastasis."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Potential anti-tumor properties through serotonin modulation; rarely discussed in pancreatic cancer context."}}
{"disease": "pancreatic neoplasm", "drug": "Imatinib", "rationale_bullets": ["Imatinib inhibits PDGFR and c-Kit pathways, which are involved in EMT regulation, potentially reducing cancer cell migration and invasion.", "Imatinib's inhibition of BCR-ABL tyrosine kinase can interfere with autophagy signaling pathways, which are crucial for pancreatic cancer cell survival under stress.", "The drug's action on PDGF receptors may reduce fibrosis, a significant barrier to drug delivery in PDAC.", "GSEA pathway analysis shows involvement in autophagy and glycolysis pathways, which are critical for pancreatic cancer metabolism and growth.", "The evidence suggests potential indirect effects on glycolysis, aligning with the Warburg effect observed in PDAC.", "Limited direct clinical evidence for Imatinib in pancreatic neoplasm, with some case reports indicating potential benefit."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Moderate confidence; potential indirect effects on glycolysis; limited direct clinical evidence."}}
{"disease": "pancreatic neoplasm", "drug": "Vinblastine", "rationale_bullets": ["Vinblastine disrupts microtubule formation, leading to mitotic arrest and activation of p53, promoting apoptosis, which is relevant given the frequent TP53 mutations in PDAC.", "Vinblastine disrupts mitochondrial function and oxidative phosphorylation, leading to decreased ATP production and increased oxidative stress in cancer cells, which aligns with the metabolic vulnerabilities of PDAC.", "GSEA pathway analysis highlights oxidative phosphorylation and mitochondrial dysfunction pathways, which are downregulated, supporting the mechanistic action of Vinblastine in targeting energy metabolism in PDAC cells.", "Indirect associations via shared genes like TP53 and STK11, which are relevant to PDAC, support the potential efficacy of Vinblastine.", "Vinblastine's mechanism of action includes promoting apoptosis through p53 activation, which is crucial for targeting TP53-mutated PDAC cells.", "Evidence from nanoparticle-based delivery systems for Vinblastine in pancreatic cancer cells suggests targeted apoptosis induction and gene expression modulation, reinforcing its potential utility in PDAC."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Moderately high confidence; significant risks; nanoparticle delivery suggested."}}
{"disease": "pancreatic cancer", "drug": "Liothyronine", "rationale_bullets": ["Liothyronine is a synthetic form of the thyroid hormone triiodothyronine (T3); thyroid hormones can influence metabolism and cellular growth.", "Potential modulation of metabolic pathways in cancer cells; thyroid hormones have been studied for their effects on cancer cell proliferation.", "Liothyronine may affect the overall metabolic state of the patient, which could influence cancer progression."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "oral", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Synthetic thyroid hormone; potential metabolic modulation; rarely discussed in pancreatic cancer context."}}
{"disease": "pancreaticcancer", "drug": "Melarsoprol", "rationale_bullets": ["Melarsoprol is an arsenic-based drug primarily used to treat trypanosomiasis.", "It has cytotoxic properties that could theoretically target cancer cells.", "High toxicity and severe side effects limit its use."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "IV", "Q7_neurotoxicity_concern": true, "Q8_supporting_evidence_references": [], "Q9_note": "High toxicity; limited use; theoretical cytotoxic properties."}}
{"disease": "pancreaticcancer", "drug": "Fenoldopam", "rationale_bullets": ["Fenoldopam is a dopamine receptor agonist primarily used for hypertension.", "It has vasodilatory effects which might improve blood flow to tumors.", "Potential for reducing tumor hypoxia and enhancing drug delivery.", "No direct evidence of efficacy in pancreatic cancer."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "IV", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Primarily used for hypertension; potential vasodilatory benefits; no direct evidence in pancreatic cancer."}}
{"disease": "pancreatic neoplasm", "drug": "niraparib", "rationale_bullets": ["Niraparib targets PARP1, which interacts with TP53, a key gene mutated in PDAC.", "Evidence from Phase II trials suggests efficacy in BRCA-mutated pancreatic cancers, relevant to PDAC.", "GSEA pathway analysis highlights DNA repair pathways, which are crucial in PDAC due to frequent mutations in DNA repair genes.", "Niraparib's mechanism involves PARP inhibition, which can be effective in tumors with defective DNA repair mechanisms, common in PDAC.", "Indirect associations via BRCA1, BRCA2, and TP53 support the relevance of niraparib in PDAC.", "Cell viability studies show niraparib's cytotoxicity in pancreatic cancer cells, regardless of BRCA status, indicating broader applicability."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Niraparib shows promise in PDAC due to its mechanism targeting DNA repair pathways; Phase II trials indicate efficacy in BRCA-mutated pancreatic cancers."}}
{"disease": "pancreaticcancer", "drug": "Emapalumab", "rationale_bullets": ["Emapalumab is an anti-interferon gamma (IFNγ) monoclonal antibody.", "IFNγ is involved in immune regulation and inflammation.", "Pancreatic cancer has a complex immune environment that may be influenced by IFNγ.", "Targeting IFNγ could modulate the immune response in pancreatic cancer."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "IV", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Emapalumab targets IFNγ; potential to modulate immune response in pancreatic cancer."}}
{"disease": "pancreatic cancer", "drug": "Somatotropin", "rationale_bullets": ["Somatotropin is a growth hormone; it may influence cancer cell proliferation.", "Growth hormones can affect metabolic processes; potential impact on tumor growth.", "Somatotropin has been studied in various cancers; relevance to pancreatic cancer is plausible."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Growth hormone influence on cancer cell proliferation; metabolic impact on tumor growth."}}
{"disease": "pancreatic neoplasm", "drug": "Pirfenidone", "rationale_bullets": ["Pirfenidone is an antifibrotic agent that inhibits TGF-β production and signaling, potentially reducing tumor growth and metastasis associated with SMAD4 loss, which is common in PDAC.", "The drug's mechanism of action includes reducing the desmoplastic stroma, a characteristic feature of PDAC, which can create a physical barrier to drug delivery and support tumor growth.", "GSEA pathway analysis highlights the TGF-β signaling pathway (down, p<0.05), which aligns with the drug's known mechanism of action and the disrupted TGF-β pathway in PDAC.", "Indirect associations via shared genes such as TERT, HIF1A, and STAT3, which are relevant to pancreatic neoplasm, support the potential efficacy of Pirfenidone in this context.", "Pirfenidone has shown potential in preclinical models to block the desmoplastic process in pancreatic cancer, which is a significant feature of PDAC.", "The drug's antifibrotic properties could mitigate the extensive fibrosis seen in PDAC, potentially improving drug delivery and reducing tumor growth."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Antifibrotic agent; potential to reduce tumor growth and metastasis; preclinical models show promise."}}
{"disease": "pancreatic cancer", "drug": "Epicriptine", "rationale_bullets": ["Epicriptine is a dopamine agonist; may influence tumor growth via dopamine receptor pathways", "Potential modulation of immune response; could impact tumor microenvironment", "Mechanistic plausibility in altering pancreatic cancer cell signaling"], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Dopamine agonist; potential impact on tumor growth and immune response; mechanistic plausibility"}}
